These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34327767)

  • 21. Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
    Kikuchi M; Nakasone H; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Sakamoto K; Kawamura K; Ishihara Y; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Yamazaki R; Kako S; Kanda J; Nishida J; Sekiguchi N; Noto S; Kida M; Hangaishi A; Usuki K; Kanda Y
    J Chemother; 2015 Feb; 27(2):99-105. PubMed ID: 25314911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
    Späth-Schwalbe E; Lange C; Genvresse I; Krüger L; Eucker J; Schweigert M; Sezer O; Budach V; Possinger K
    Anticancer Drugs; 2002 Apr; 13(4):395-403. PubMed ID: 11984085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
    Khaled HM; Zekri ZK; Mokhtar N; Ali NM; Darwish T; Elattar I; Gaafar R; Moawad MS
    Ann Oncol; 1999 Dec; 10(12):1489-92. PubMed ID: 10643541
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
    Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
    Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
    Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
    Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
    Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
    Bessell EM; Burton A; Haynes AP; Glaholm J; Child JA; Cullen MH; Davies JM; Smith GM; Ellis IO; Jack A; Jones EL;
    Ann Oncol; 2003 Feb; 14(2):258-67. PubMed ID: 12562653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-Hodgkin lymphoma in elderly patients: experience at Taipei Veterans General Hospital.
    Bai LY; Yang MH; Chiou TJ; Liu JH; Yen CC; Wang WS; Hsiao LT; Chao TC; Chen PM
    Cancer; 2003 Sep; 98(6):1188-95. PubMed ID: 12973842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Long term results for intermediate and high grade localized non Hodgkin lymphoma, treated with chemotherapy and radiotherapy].
    Ramírez V P; Ocqueteau T M; Alvarez Z M; Bertín C-M P; Lira V P; Bustos C M; Besa de C P
    Rev Med Chil; 2006 Nov; 134(11):1409-16. PubMed ID: 17277854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.
    Sharma R; Cunningham D; Smith P; Robertson G; Dent O; Clarke SJ
    BMC Cancer; 2009 May; 9():153. PubMed ID: 19450285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma.
    Gordon MJ; Duan Z; Zhao H; Nastoupil L; Iyer S; Ferrajoli A; Danilov AV; Giordano SH
    JCO Clin Cancer Inform; 2024 Apr; 8():e2300223. PubMed ID: 38684043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.
    Gopal S; Fedoriw Y; Kaimila B; Montgomery ND; Kasonkanji E; Moses A; Nyasosela R; Mzumara S; Varela C; Chikasema M; Makwakwa V; Itimu S; Tomoka T; Kamiza S; Dhungel BM; Chimzimu F; Kampani C; Krysiak R; Richards KL; Shea TC; Liomba NG
    PLoS One; 2016; 11(3):e0150445. PubMed ID: 26934054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
    Cohen JB; Geyer SM; Lozanski G; Zhao W; Heerema NA; Hall NC; Nagar VA; Hemminger JA; Jones JA; Porcu P; Christian BA; Baiocchi RA; Maddocks KJ; Flynn JM; Devine SM; Blum KA
    Cancer; 2014 Jun; 120(11):1677-85. PubMed ID: 24578014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy.
    Johnson PC; Jacobson C; Yi A; Saucier A; Dhawale TM; Nelson A; Lavoie MW; Reynolds MJ; Topping CEW; Frigault MJ; El-Jawahri A
    J Natl Compr Canc Netw; 2021 Mar; 19(8):928-934. PubMed ID: 33706257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA.
    Trebouet A; Marchand T; Lemal R; Gyan E; Broussais-Guillaumot F; Guillermin Y; Monjanel H; Salles G; Le Gouill S; Godmer P; Fruchart C; Damaj G; Feugier P; Thieblemont C; Maynadié M; Monnereau A; Troussard X; Rossille D; Lamy T; Houot R
    Ann Oncol; 2013 Oct; 24(10):2612-2618. PubMed ID: 23970017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
    Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
    Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
    López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
    Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.